Immix Biopharma (IMMX) Net Income towards Common Stockholders (2021 - 2026)
Quarterly results put Net Income towards Common Stockholders at -$10.1 million for Q1 2026, down 122.05% from a year ago — trailing twelve months through Mar 2026 was -$35.0 million (down 4300.29% YoY), and the annual figure for FY2025 was -$29.4 million, down 1759.03%.
Immix Biopharma has reported Net Income towards Common Stockholders over the past 6 years, most recently at -$10.1 million for Q1 2026.
- Net Income towards Common Stockholders reached -$10.1 million in Q1 2026 per IMMX's latest filing, up from -$10.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $15.3 million in Q4 2024 and bottomed at -$10.7 million in Q4 2025.
- Median Net Income towards Common Stockholders over the past 5 years was -$4.4 million (2024), compared with a mean of -$3.8 million.
- The largest annual shift saw Net Income towards Common Stockholders tumbled 649.04% in 2022 before it skyrocketed 396.83% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$3.8 million in 2022, then crashed by 35.67% to -$5.2 million in 2023, then surged by 396.83% to $15.3 million in 2024, then crashed by 169.84% to -$10.7 million in 2025, then increased by 5.62% to -$10.1 million in 2026.
- Business Quant data shows Net Income towards Common Stockholders for IMMX at -$10.1 million in Q1 2026, -$10.7 million in Q4 2025, and -$7.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.63 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | -10.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -10.69 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | -7.15 Mn |
| Jun 30, 2024 | -4.41 Mn |
| Mar 31, 2024 | -5.33 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Sep 30, 2023 | -4.34 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -2.50 Mn |
| Dec 31, 2022 | -3.80 Mn |
| Sep 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.76 Mn |
| Sep 30, 2021 | -403,265.00 |
| Jun 30, 2021 | -208,638.00 |
| Mar 31, 2021 | -1.02 Mn |